At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 124 enrolled
Drug / intervention
regadenoson +4 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2, Open-Label, Randomized, Cross-Over Study of Regadenoson in Subjects Undergoing Stress Myocardial Perfusion Imaging by Multidetector Computed Tomography (MDCT) and Single Photon Emission Computed Tomography (SPECT)
In Brief
A Phase 2 clinical trial evaluating regadenoson, technetium Tc99m sestamibi /technetium Tc99m tetrafosmin, and 3 other interventions for Coronary Artery Disease (CAD). Completed, enrolled 124 participants across 11 sites.
Detailed Summary
The purpose of this study is to compare Multidetector Computed Tomography (MDCT) and Single Photon Emission Computed Tomography (SPECT) stress myocardial perfusion imaging (MPI) with regadenoson in order to detect the presence or absence of reversible defects.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCoronary Artery Disease (CAD)
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedApr 2011
Enrollment StartApr 2011
Primary CompletionJul 2012
TodayJul 2026
First PostedApr 13, 2011
Enrollment StartApr 26, 2011
Primary CompletionJul 2, 2012
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 15.2 years ago
Interventions
regadenosondrug
Administered by intravenous bolus.
technetium Tc99m sestamibi /technetium Tc99m tetrafosminradiation
Administered by intravenous infusion
Contrastradiation
Administered by intravenous infusion.
Single Photon Emission Computed Tomographyprocedure
Procedure/Surgery
Multidetector Computed Tomographyprocedure
Procedure/Surgery